Surrozen (SRZN) Stock Price

Surrozen Price

NASDAQ·CLOSED
29.51
​
Market closed

Revenue at Surrozen has contracted by 34.7% per year over the past 3 years to 3.48 M USD. Surrozen's net margin stands at -6,960.8%, down from -221.4% several years earlier. Analysts set a median price target of 44.00 USD, implying 49.1% above the current price. Of 12 analysts, 11 rate the stock a buy — an overall Buy consensus.

Surrozen stock price

Access this data via the Eulerpool API

Surrozen business model & stock analysis

Surrozen, Inc. is a clinical stage biotechnology company. The company is headquartered in South San Francisco, California and currently employs 74 full-time employees. The company went IPO on 2020-11-23. The firm is engaged in discovering and developing drug candidates to selectively modulate the Wnt pathway, a critical mediator of tissue repair, in a range of organs and tissues. The firm's lead product candidates are multi-specific, antibody-based therapeutics that mimic the roles of naturally occurring Wnt or R-spondin proteins, which are involved in activation and enhancement of the Wnt pathway. Its two technologies, Surrozen Wnt signal Activating Protein (SWAP) and Surrozen Wnt signal Enhancers Engineered for Tissue Specificity (SWEETS), enable it to potently and selectively modulate Wnt signaling through the generation of Wnt and R-spondin mimetics. SWAP molecules are designed to mimic the activity of naturally occurring Wnt proteins. SWEETS molecules are designed to amplify the body’s response to naturally occurring Wnt proteins. Its product candidates include SZN-1326, SZN-043 and SZN-413.

Frequently asked questions about Surrozen

Analysts currently set an average price target of 44.00 USD for the Surrozen stock (median: 44.00 USD), implying +49.1 % versus the latest price. The consensus is based on 12 analyst ratings.

12 analysts currently rate the Surrozen stock: 11 recommend buying, 1 holding and 0 selling. For 2026, analysts expect Surrozen to generate revenue of 10.74 M USD and earnings per share of -6.61 USD.

Converted at the current exchange rate, the Surrozen share trades at 26.33 EUR (29.51 USD).

The Surrozen share (SRZN) is listed on 1 stock exchanges, including: NASDAQ (SRZN).

The expected revenue of Surrozen is 10.74 M USD. This figure is based on current financial data and reflects the company's business performance.

The expected profit of Surrozen is -60.12 M USD. The net profit reflects the company's profitability after deducting all expenses.

The price-to-earnings ratio (P/E) of Surrozen is currently -4.47. The P/E ratio compares the current share price to the earnings per share and helps investors assess the valuation of the Surrozen stock.

The price-to-sales ratio (P/S) of Surrozen is currently 25.00. The P/S ratio compares the market capitalization to the annual revenue and serves as a valuation metric for the Surrozen stock.

The Eulerpool Quality Score for Surrozen is 2/10.

The ISIN of Surrozen is US86889P2083. The ISIN (International Securities Identification Number) is a globally unique identifier for securities.

The ticker of Surrozen is SRZN. The ticker symbol is used to trade Surrozen shares on the stock exchange.

Fair ValueTerminal
26.85 USD
Over-/UndervaluationTerminal
Fairly valued
Sector
Industry
Biotechnology
Number of shares
Employees
Revenue per Employee
79,022.73 USD
Revenue growth Ø5 years
EBIT growth Ø5 years
Net Income growth Ø5 years
Website surrozen.com
Currency
USD
Initial public offering
Nov 23, 2020
ISIN
US86889P2083
Cusip
86889P109
Market capitalization
252.90 M USDMicro Cap
52-Week Range
PEG
0.12
P/E ratio
P/Ee 2026
-4.47
P/Ee 2027
-8.68
P/Ee 2028
-8.59
P/Ee 2029
-8.04
P/Ee 2030
-7.30
P/Se
25.00
EV/EBIT
—
P/B Ratio
6.67
ROE (Return on Equity)
ROA (Return on Assets)
ROCE (Return on Capital Employed)
ROIC (Return on Invested Capital)
129.79 %
Last updated Oct 10, 2026, 4:35 AM

Surrozen Peer Group

Surrozen Ticker

NASDAQ · SRZN

All fundamentals and in-depth analysis of Surrozen

Our stock analysis for Surrozen stock includes important financial indicators such as revenue, profit, P/E ratio, P/S ratio, EBIT, as well as information on dividends. We also assess aspects such as stocks, market capitalization, debt, equity, and liabilities of Surrozen. If you are looking for more detailed information on these topics, we offer comprehensive analyses on our subpages.